WO2000025726A2 - Multilayer antibacterial treatment device - Google Patents
Multilayer antibacterial treatment device Download PDFInfo
- Publication number
- WO2000025726A2 WO2000025726A2 PCT/US1999/025893 US9925893W WO0025726A2 WO 2000025726 A2 WO2000025726 A2 WO 2000025726A2 US 9925893 W US9925893 W US 9925893W WO 0025726 A2 WO0025726 A2 WO 0025726A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silver
- recited
- layer
- fabnc
- bactencidal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/63—Crystals
Definitions
- the present invention relates to multilayer devices having physiologically beneficial antimicrobial, antifungal, and antiviral properties.
- the present invention relates to silver-containing devices for use as wound packing materials, as dressings for the care and treatment of surface wounds, and as deodorizing inserts in socks, stump socks, athletic shoes, sole and heel pads, garment shields, and the like.
- Wound healing is a cellular process which is t ⁇ ggered by the occurrence of an injury (as used herein, the terms “wound” and “injury” refer to tissue damage or loss of any kind, including but not limited to cuts, incisions (including surgical incisions), abrasions, lacerations, fractures, contusions, burns, amputations, and so forth).
- wound is believed to be controlled by a biophysiological feedback mechanism that monitors the extent of the injury and controls cellular activity m the injured area to produce the types and numbers of cells needed to accomplish a repair.
- a metal with "antibiotic,” “antimicrobial,” “cidal,” “bactericidal” and/or “bacte ⁇ static” properties is broadly defined as a metal that is active against at least one pathogenic microorganism, including but not limited to bacteria, protozoa, fungi, ⁇ ckettsiae, and viruses. Bacte ⁇ cidal agents kill microorganisms, whereas bacte ⁇ static agents prevent their growth and multiplication).
- Topical preparations that contain silver or silver compounds— silver nitrate, silver sulfadiazine, colloidal silver compositions, silver-protein compounds such as ArgyrolTM , and so forth— are widely used in medicine.
- ointments containing silver sulfadiazine are widely used for the treatment of infected burns.
- osteomyelitis infections of bone (i.e., osteomyelitis) remained difficult to treat because the limited blood supply to this tissue precluded obtaining adequate local levels of systemically administered antibiotics. The appearance of mixed and antibiotic-resistant infections has further complicated this situation. Even today, the only effective treatment for osteomyelitis remains p ⁇ ma ⁇ ly surgical, and includes adequate wound deb ⁇ dement, leaving the wound open du ⁇ ng healing, and supplementing with appropnate systemic antibiotics.
- silver as an antimicrobial agent is at least partly determined by the delivery system. Most silver compounds that dissociate readily yield cations that are highly toxic to human tissues, and therefore are not considered suitable for medical use. Less-toxic compounds, including silver sulfadiazine cream (widely used in the treatment of burns) and silver mtrate solution, do not dissociate readily. These topical compounds must therefore be re-applied frequently to maintain their clinical efficacy.
- Iontophoretic i.e., elect ⁇ cally-generated
- silver ions which can penetrate more deeply into the tissues than silver ions from topical compounds, have been found to inhibit bacte ⁇ al and fungal growth in vivo and in vitro at current densities as low as 10 nA/ m 2 .
- Silver ions are effective even against antibiotic-resistant strains of bacte ⁇ a and fungi.
- Iontophoretic silver treatment is somewhat more effective than treatment with silver compounds, with generally the same spectrum of activity as that of silver nylon.
- the effects of electrically-generated silver ions are desc ⁇ bed in a number of publications, including the following: J. A.
- Silver and other metals are used in a number of wound dressings, in the form of pure metal, metal salts, or other compounds.
- McKnight, et al. disclose a laminated collagen dressing for treating burn (U.S. Patent No. 3,800,792).
- Their dressing is made from a layer of reconstituted collagen film laminated to a thin continuous layer of an inert polymer material such as polyurethane.
- the collagen film may contain finely divided silver metal particles, added by soaking the d ⁇ ed film in Tollen's reagent to oxidize excess glutaraldehyde and deposit silver metal on the accessible surfaces of the collagen fibers Weaver, et al.
- a disposable, multilayer electrode that includes a nonconductive cover sheet, a nonmetalhc, conductive disperser sheet (preferably made of carbon-containing silicon rubber), and a non-adhe ⁇ ng wound contact sheet
- This device is designed to prevent migration of metal ions into the wound being treated
- Fabo U.S. Patent No. 5,340,363 discloses a dressing that includes an outer absorbent layer and an inner porous, hydrophobic layer knitted of elastic threads and encapsulated by a soft, hydrophobic silicone or polyurethane gel.
- the gel can be used as a earner for antibacte ⁇ al agents such as zinc, pain-relieving substances, and agents that stimulate wound repair. Klippel, et al.
- micronized allantoin as a earner for a bacte ⁇ cidal or bacte ⁇ static ingredient (such as silver citro allantoinate) that is dispersed on the surface of a plastic air splint or other bandaging product (U.S. Patent No. 3,830,908).
- Stoberg makes a dressing of absorbent, metal-coated fibers, such as carding fleece coated with aluminum and backed by compressed cellulose, and polyamide fibers coated with vacuum-deposited silver (U.S. Patent No. 2,934,066).
- Matson U.S. Patent No. 4,728,323 coats a substrate (nylon fab ⁇ c, polymeric film, fiberglass, gauze or polyurethane foam) with a film of a silver salt deposited by vapor or sputter coating techniques.
- Altemativeh fibers can be coated and then woven or knitted into a fabnc.
- Konikoff U.S. Patent No. 4,142,521) shows a bandage or surgical sponge matenal incorporating one or more electret elements, each electret providing a small electrostatic field to the area of the wound.
- Rogozinski U.S. Patent No. 5,395,398 discloses a composite dressing that includes an elliptical or circular pad with a pure silver anode surrounded by a nng of base metal, a dorsal support layer, surface contact layers of electncally-conductive hydrogel polymer, and two battery-powered generators.
- Silver, et al. provide a wound dressing made of biocompatible, biodegradable collagen sponge with carbon or metal (including silver) electrodes inserted therein (U.S. Patent No. 4,703,108) The electrodes do not release metallic ions into the wound, and are removed surgically once the wound heals.
- D'Alerta's patch includes an electronic circuit for dehve ⁇ ng a pulsed stimulus, circuitry including a cathode and an anode, a double-sided adhesive layer, a top layer which seals the circuit layer from moisture, and a backing layer (U.S. Patent No. 5,423,874).
- a DC (direct current) voltage to the conductive layer drives silver ions into the wound to enhance tissue growth and inhibit bacte ⁇ al growth; application of transcutaneous AC (alternating current) is used for post-operative pain relief.
- Seiderman U.S. Patent No. 4,767,401 descnbes a bandage-like device used for iontophoretic administration of medicaments, including silver-protein colloids.
- the device includes a metal foil electrode (preferably aluminum), and makes use of the slight inherent negative elect ⁇ c charge proximate a wound site to generate a small electnc field at the site.
- silver metal or a topical composition such as silver nitrate solution or silver sulfadiazine cream
- beneficial effects are believed to be limited by the achievable local concentration of silver ions.
- these effects are manifested pnmanly at the contact surface and immediately adjacent tissues.
- Another widespread concern relates to objectionable body odors, both normal odors and those a ⁇ sing from infections, metabolic disorders, and syndromes that give rise to profuse, malodorous perspiration.
- objectionable body odors are still a problem for many people. Body odor is largely due to bactenal action in fluid secretions, particularly perspiration.
- sweat glands also termed sudonferous glands: small, tubular glands found almost everywhere on the body, but which are especially numerous in the armpits and on the palms and soles.
- the sweat glands play an important role in regulating body temperature: these glands secrete moisture, which evaporates, cools the body surface, and helps maintain normal body temperature.
- the feet are a major source of objectionable odors. Even though the soles contain large numbers of sweat glands, perspiration odor from the feet is not particularly noticeable when going barefoot or weanng sandals. However, feet encased in shoes, with or without hose or socks, quickly develop a distinctive "locker-room" odor which most people perceive as unpleasant. Odors of this nature are an especial concern to amputees, who typically wear close-fitting tubular socks over a residuum to help cushion a prosthesis. People have approached the problem of masking or eliminating objectionable body odors in many different ways.
- objectionable body odors are a source of embarrassment and discomfort to large numbers of people.
- Deodorants and antiperspirants are helpful in mastang or reducing odors due to underarm perspiration, and dress shields protect clothing by absorbing perspiration.
- many people cannot use common deodorants and antiperspirants due to allergies.
- presently-available deodorants and antiperspirants do little to alleviate locker-room odor due to bacte ⁇ al growth.
- the present invention is a multilayered antimicrobial device for therapeutic and prophylactic use.
- the device includes a first layer consisting of at least one sheet of a flexible, conformable, bactencidal fabnc. Additional layers may include at least one sheet of moisture-absorbing material adjacent the bactencidal fabric, a moisture reservoir, and, optionally, a thin, flexible outer layer of moisture-impermeable material that serves as an occlusive bar ⁇ er to direct moisture (wound exudates, perspiration, etc.) to the target area.
- the edges of these layers are preferably bonded together by heat/pressure bonding techniques known in the art.
- the bactencidal fabnc contains a metal such as silver that is effective against a broad spectrum of microorganisms, including but not limited to sepsis-causing bacteria and odor- causing bacte ⁇ a.
- a metal with "antimicrobial,” “bactencidal” and/or “bactenstatic” properties is broadly defined as a metal that is active against at least one pathogenic agent, including but not limited to bacteria, protozoa, fungi, nckettsiae, and viruses.
- the silver (or other bactencidal metal) is preferably in a mechamcally stable form that remains bound to the fabnc substrate when dry, but that releases useful amounts of silver ions when moistened by a liquid such as water, saline solution, wound exudate, perspiration, and so forth.
- a liquid such as water, saline solution, wound exudate, perspiration, and so forth.
- the device itself is durable, nontoxic, nonhazardous, substantially nonallergemc and nonirntatmg, and inert until activated by contact with a suitable liquid (water, perspiration, wound exudate, hydrocolloid, etc.).
- a device When used in the care and treatment of skin infections, ulcers, surface wounds (including surgical incisions) and the like, a device according to the present invention is effective in slowing the growth of microorganisms such as bactena and fungi in the treated area.
- the device also provides an effective prophylactic measure against airborne contaminants and opportunistic infections.
- the device When installed inside a shoe, sock, stump sock, pantyhose, or shoe, the device is activated upon hydration with perspiration (if desired, the device may be pre-moistened with water or other suitable liquid prior to use).
- the device is effective in slowing the growth of odor-causing bactena that thnve in the relatively warm, relatively moist environment of shod feet, thereby slowing the onset of perceptible locker-room odor.
- bactencidal fabric which contains a bacte ⁇ cidal/bacte ⁇ static metal (preferably silver) on a flexible, conformable, moisture- absorbing, nonallergemc, non-adhenng fabnc substrate.
- a bacte ⁇ cidal/bacte ⁇ static metal preferably silver
- the fabnc may also have a good "hand" and an esthetically-pleasing appearance.
- the bactencidal fabnc may be sufficiently thick that it acts as a stent, that is, it can retain moisture and is capable of seeping up wound exudates.
- the edges of the sheets (and of the absorbent layer, if present) are preferably bonded together by heat/pressure bonding techniques known in the art.
- Suitable silver-containing fabrics for the invention include felted, loop, matted, pile, tricot, warp knit, and other silver nylon fabncs.
- the bactencidal fabnc contains at least approximately 2 wt.% silver, more preferably at least approximately 10-15 wt.% silver; however fabncs with silver contents outside these ranges may also be useful.
- Another feature of the present invention is the provision of at least two sheets of bactencidal fabnc in the form of a layered or laminar structure, each sheet having a useful metal content.
- useful fabncs generally contain at least approximately 2 wt.% silver.
- Fabncs that contain more silver by weight are generally believed to have more available silver for treatment purposes than those that contain less silver, whether the additional silver is in the form of a thicker coating, a greater admixture of silver-coated fibers, or smaller-diameter fibers that provide a larger silver-coated surface area.
- Provision of two or more layers of silver-containing fabnc in the present invention is predicated upon the surprising discovery that these are as effective as a single layer with approximately the same silver content— even where the single layer contains the same amount of silver as the two layers combined. That is, two layers provide substantially the same amount of silver ions at the treatment site as a single layer having twice the silver content by weight.
- Each sheet contains a biologically-effective amount of mechanically-stable silver on a flexible, conformable, non-adhering fabric substrate such as nylon.
- a treatment device with two or more silver-containing sheets delivers more useful silver ions to the treated area, without the disadvantages of powdenng and flaking associated with fabrics having higher silver contents.
- W_th a sufficiently large number of silver-containing sheets, however, the overall flexibility of the device and the added amount of free silver ions per additional sheet tend to decrease.
- the absorbent layer of the device which, if present, is made of a moisture-absorbing material of sufficient thickness to serve as a stent. The moisture-absorbing material seeps up wound exudates, maintains the moist condition of the wound, and furthers migration of silver ions to the treatment site.
- Suitable matenals include soft, flexible, conformable fabrics made of natural fibers such as cotton, synthetics such as polyester, rayon, dacron, polyurethane, acrylic and modacry c, thermoplastics, and so forth.
- this layer may itself contain silver or other bactencidal metal, for example, at least approximately 2 wt.% silver and more preferably at least approximately 5-10 wt.% silver.
- the moisture-impermeable layer which serves as an occlusive barner that helps entrain fluids and direct them to the bactencidal fabnc.
- the moisture-impermeable layer is also gas-permeable to further ventilation of the treated area. Suitable matenals include Goretex® and the types of plastics used in Band-Aid® type dressings.
- the treatment device may consist simply of one or more sheets of silver-containing fabnc that, when moistened by any suitable liquid (including but not limited to water, wound exudates, and perspiration), release silver ions that act to slow the growth of microorganisms at the treated site.
- a device of this type is useful as a wound dressing or wound packing matenal; it may also be used prophylactically to slow the growth of odor-causing bactena in socks, stump socks, shoes, garment shields, etc.
- This type of device may also include a sheet of some fabnc that is capable of absorbing at least some moisture.
- the device includes, in sequence, a sheet of moisture-impermeable, gas-permeable material such as Goretex®, a sheet of moisture-absorbing matenal, and one or more sheets of silver- containing fabric, the combination being sufficiently flexible to conform generally to the area being treated.
- a treatment device according to the invention can be dimensioned according to the intended use; it can be made by any convenient techmques known in the art, of readily available, generally inexpensive matenals. It can be provided in a convenient form for a vanety of applications, ranging from prepackaged, prestenhzed individual units such as BandA ⁇ d®-type dressings to rolls or sheets that can be cut to size as needed.
- the device can be applied to surface wounds such as cuts (including surgical incisions), scrapes, and burns. It can also be applied to intact skin to treat localized infections.
- the device includes a connector for making electncal contact with a power source used for iontophoretic treatment.
- FIG. 1A-1C show the results of in vitro tests of several silver-containing products
- Fig. 2 is an exploded, perspective view of a wound treatment device according to the present invention
- Fig. 3A is a cross-sectional view of the device of Fig. 1;
- FIGS. 3B and 3C are detail, cross-sectional views of additional embodiments of a device according to the present invention.
- Fig. 4 is a plan view of a finger-tip dressing according to the present invention
- Figs. 5A and 5B are cross-sectional views of wound packing matenals according to a preferred embodiment of the present invention
- Fig. 6A is a perspective view of another wound packing material according to a preferred embodiment of the present invention.
- Fig. 6B is a perspective view of a dispenser for a wound packing matenal according to the invention.
- Fig. 7A is a perspective view of a deodonzing insert according to a preferred embodiment of the present invention.
- Fig. 7B is a cross-sectional view of the insert of Fig. 7A;
- Fig. 7C is a cross-sectional view of another deodorizing product according to the invention.
- Figs. 8A and 8B are cross-sectional views of iontophoretic treatment devices according to the present invention.
- Figs. 9A and 9B are perspective views of additional devices according to the present invention.
- Fig. 9C is a detail, cross-sectional view of the fastener of the device of Fig. 9B .
- the terms “horizontal,” “vertical,” “left,” nght,” “up,” “down,” as well as adjectival and adverbial derivatives thereof, refer to the relative onentation of the illustrated structure as the particular drawing figure faces the reader.
- the effectiveness of silver against several strains of wound sepsis and odor-causing bactena was tested in vitro using five silver-containing fabrics.
- the bactena tested included standard bactenal strains obtained from the Ame ⁇ can Type Culture Collection (“ATTC”) and multiply drug-resistant (“MDR”) climcal isolates (“CI”) obtained from the Burn Trauma Intensive Care Unit of the University of Utah Medical Center.
- Products 2 and 3 differed in that Product 2 was pre-treated by exposure to the atmosphere; Product 3 was untreated. Also tested were the ArglaesTM controlled-release film dressing (Product 6), and 1% silver sulfadiazine (Silvadine®) cream on a non-silver-impregnated nylon fabnc (Ommshield, Inc.; Product 7). The silver content of an 18 mm disc of each product is listed in Table I .
- Test species included Acinetobacter.
- Test Configuration A Discs of Products 1-7 were tested for the ability to continue to emit silver ions with continued use. The discs were applied directly to newly-inoculated Kirby-Bauer plates filled with approximately ninety (90) mL of Mueller-Hinton Agar, and moistened with sterile 0.85% saline. Each Kirby-Bauer plate contained three disks which were treated with one of the seven products.
- the plates were incubated for 48 hours, after which zones of inhibition (as measured outward from the edge of the disc) were read alter 48 hours for each disc (1st microbial challenge).
- the measured zone of inhibition for each disc was defined as the distance in millimeters between the edge of the disk and the outer edge ol the zone of inhibition.
- the discs were then applied to fresh Kirby-Bauer plates inoculated with the same bacteria and incubated for an additional 48 hours, and the zones of inhibition were measured C2nd microbial challenge) This procedure was repeated a third time (3rd microbial challenge). Test results are shown in Tables II and III.
- MDR P. aeruginosa
- CI #2 2 2.83 10.00 5.50 3 3.50 9.67 10.50 4 3.50 7.50 9.50 5 4.50 7.00 9.33 6 2.00 4.00 0.00 7 3.67 1.67 0.00
- Test Configuration B The test protocol was the same as described above for Configuration A, with the exception that the contact surfaces of discs removed from the Kirby-Bauer plates were washed with sterile 0.85% saline before placement on newly- inoculated Kirby-Bauer plates. Representative test results are shown in Table IV.
- MDR P. aeruginosa
- Test Configuration C The test protocol was the same as described above for Configuration A. Discs were left in place on inoculated Kirby-Bauer plates for five (5) days, and were re-moistened with saline after 72 and 96 hours (i.e., on days 3 and 4). Zones of inhibition were read every 24 hours. Test results are shown in Table V.
- Product No. 5 was the most effective in absolute terms. Despite a lower silver content, Product No. 2 had zones of inhibition similar to those of Product No. 5 for Acinetobacter. 1-4, suggesting that use of the aged pile fabric may enhance effectiveness. Effectiveness against Corynebacterium xerosis depended on the test configuration and the challenge, and none of the tested products was more than minimally effective against Enterobacter. cloacae, E. coli, and P. mirabilis.
- Products 1-5 and 7 were found to be effective against odor-causing bacteria (products 2 and 3 were more effective against Corynebacterium xerosis than Products 1, 4, and 5). Surprisingly, the overall effectiveness of Product 2 (treated surface) was greater than that of Product 3 (untreated surface). These results indicate that silver-containing fabric is effective in reducing the multiplication of odor-causing bacteria in vitro.
- SER silver effectiveness ratio
- SER is a relative measure of each product's effectiveness on the basis of its silver content.
- Figs. 4A-C are plots of the SER for Microbial Challenges 1, 3, and 5 for Test
- Configuration C across all 16 microorganisms.
- the tested microorganisms are generally arranged in decreasing order of product effectiveness (that is, there is a downward trend in product effectiveness when scanning from left to right).
- Product 1 tended to have the largest SERs; thus, the values for this product are connected by solid lines. Any points above the line indicate a product superior to Product No. 1 , having a larger SER associated with that product for that specific microorgamsm.
- Products 2 and 3 are notably effective against Acinetobacter. (Table IV); Products 3 and 5 are effective against the odor-causing bacterium Corynebactenum xerosis (Table IV); Products 2 and 3 are effective against Staphylococcus epidermidis (Table V).
- test fabnc silver-containing nylon
- control fabnc was identical save for the silver coating.
- a total of eighteen 1" (about 2.5 cm) square pieces of the test and control fabncs were prepared, and each piece was placed into a ste ⁇ le 50 mm x 9 mm Pet ⁇ dish.
- a challenge suspension consisting of a 0.55 mL aliquot of approximately 1.0 x 10 9 CFU/mL in 50% (v/v) fetal bovine serum, prepared according to standard techniques, was inoculated onto each fabnc piece; six such pieces were inoculated with each challenge suspension for each product. Airtight lids were placed onto the dishes containing the inoculated product pieces, and the dishes were incubated at 35° ⁇ 2° C for periods of thirty minutes, four hours, and twenty-four hours.
- IP Initial Population
- IL Inoculum Level
- P ⁇ Microorganism Population
- % Difference 100 ((IL - P ⁇ IL).
- Table VII Average populations after exposure (Log 10 and CFU/product piece) for silver-containing nylon and control products for the three microorganisms tested at each of three exposure times (30 minutes, 4 hours, and 24 hours).
- Table VIII Log 10 Differences and % Differences for silver-containing nylon and control products for the three microorganisms tested at each of three exposure times (30 minutes, 4 hours, and 24 hours).
- test product silica-containing nylon fabnc
- the test product reduced the challenge populations of all three microbial species tested as compared to the control product.
- Device 10 may include a thin, flexible outer layer 12 that serves as a cover, an intermediate layer 14 of absorbent matenal attached to the medial portion of layer 12 by any suitable technique (for example, with an adhesive 16), and at least one inner layer 18 (preferably a laminar structure with at least two sheets 18a, 18b of silver-containing fabnc) to be described further below.
- the edges of layer 12 may be coated with a skin-contact adhesive 20, protected with a removable stnp of material (not shown) that is peeled off just pnor to use.
- the edges of layer 14 (if present) and sheets 18a, 18b may be attached together by any convenient technique, including but not limited to application of heat and pressure, embossing, cnmpmg, sonic welding, needle punching, and biocompatible adhesives such as adhesive 16. However, techmques which avoid the use of adhesives, fixatives, and so forth are preferred.
- Outer layer 12, if present, is preferably a sheet of electncally non-conducting, substantially water-impermeable material that aids in keeping optional intermediate layer 14 and sheets 18a, 18b moist while device 10 is in use to help promote healing.
- Layer 12 may also serve as an occlusive barrier that entrains fluids and directs them to silver-containing layers 18a, 18b.
- Layer 12 may include a plurality of perforations 22 therethrough to provide additional ventilation of the wound surface if desired.
- layer 12 is preferably a semi permeable matenal (air and gas-permeable but water-impermeable), that functions as a semiocclusive membrane to slow the rate of water loss.
- Layer 12 is preferably somewhat larger than layers 14 and 18a, 18b to permit application of adhesive 20 to the edges (Fig. 2A) .
- Suitable matenals for layer 12 include Goretex®, vinyl, polyethylene, and plastics such as those used in many commercially-available dressings (BandAid®, Curad®, etc.).
- Layer 14 is a sheet of soft, flexible, coniormable, moisture-absorbent matenal of adequate thickness to serve as a stent, that is, a material that can retain water and is capable of seeping up wound exudates, etc. (layer 14 may be moistened with water, normal saline, or other suitable liquid prior to or dunng use of device 10).
- Suitable matenals include cotton, polyester, rayon, dacron, polyurethane, polypropylene, acrylics and modacryhcs, polyvinyl acetate or other synthetic matenals, thermoplastic matenals, or combinations thereof, in woven, nonwoven, foam, or sponge-like form.
- Layer 14 need be no more than approximately 0.1-0.5 cm thick for most applications; however, thicker layers may be useful when device 10 is used in the care of relatively large draining wounds in excess of 4 in 2 in size or thereabouts. Matenals that are at least somewhat compressible may be useful for maintaining good contact between inner layer 18 and the treated area.
- device 10 includes a inner, laminar layer having at least two adjacent sheets 18a, 18b of silver-containing material.
- Sheets 18a, 18b are preferably made of a substrate matenal that is dimensionally stable, biologically inert, easily handled whether moist or dry, substantially non-adhenng (that is, the material does not normally adhere to skin, exposed tissues, etc.).
- the substrate matenal is one that maintains its structural integrity in use, that is, the substrate fibers do not easily become dissociated from sheets 18a, 18b under normal conditions (fabrics made of chopped fibers, and fabncs that "shed” or "pill” easily are generally not suitable for use with the invention).
- Sheets 18a, 18b, like layer 14 are at least somewhat flexible and conformable, and are made by any convenient process that produces a matenal with at least approximately 2 wt.% silver (preferably at least approximately 5 wt.% silver, more preferably at least approximately 15 wt.% silver). Lower silver concentrations may also be useful for some applications.
- Suitable substrate matenals for sheets 18a, 18b include, but are not limited to, polymers such as nylon, dacron, rayon, polyester, acrylics and modacryhcs, polyamides, polyimides, polyolefins, polyphenylenes, acetates, and other natural and synthetic fibers and blends thereof.
- Bicomponent fibers also known in the art as composite fibers may also be useful where the individual layers of device 10 are to be bonded together. These types of fibers consist of two components of different melting or softening points so that, when a fibrous web of such fibers is heated to a temperature above the lower of the two softening points but below the higher softening point, one of the two components softens and bonds the fibers together.
- Useful fibers may vary broadly in basis weight and structure, ranging from very fine fibers having a basis weight of less than 5 denier to coarser fibers of 50 denier or more.
- the substrate is preferably manufactured of biologically inert, nonconductive, nommmunogemc fibers (since many people are sensitive to certain fibers, the substrate is preferably also nonallergemc or hypoallergemc).
- the fabnc substrate of sheets 18a, 18b incorporates or is coated with useful amounts of silver by any convenient technique.
- the substrate may be a woven, knitted, or nonwoven silver-plated fabnc.
- the substrate may be made of a combination of silver-coated (or silver-impregnated) and plain fibers.
- Suitable matenals for sheets 18a, 18b include silver-impregnated warp knit nylon fabric, silver-impregnated nylon pile fabnc, and other fabrics made by Ommshield, Inc., Swift, Inc., Sauquoit Industnes, and other manufacturers.
- Other useful fabrics include polyesters, polyethylenes, rayons, acrylics, and combinations thereof that contain useful amounts of silver.
- layer 14 contains at least approximately 2 wt.% silver, more preferably at least approximately 5-10 wt.% silver.
- Suitable matenals include silvered and plain nylon fabnc made by Ommshield, Inc., Sauquoit Industries and other manufacturers; however, other matenals may also be useful for the practice of the invention.
- Layers 14, 18 may be made by weaving, knitting, felting, blowing, or other convenient process.
- Silver (or some other metal with medically useful properties) is added to sheets 18a, 18b (and layer 14, if desired) by vapor coating, aerosolized deposition, sputter coating, chemical deposition, plating, or other techniques known in the art. Individual fibers can be coated and then worked (woven, knitted, crocheted, felted, blown, etc.) into a fabnc; alternatively, silver may be added to the fimshed fabnc. Useful fabrics may contain as little as 5-10% or as much as 100% silver-coated fibers.
- the fabnc preferably contains enough silver so that sheets 18a, 18b have a specific resistance no greater than approximately 5 ⁇ /cm (more preferably, no greater than approximately 1 ⁇ /cm). However, fabncs with higher specific resistances (as high as 10 ⁇ cm or more) may also be useful.
- the added silver is in a highly purified form, that is, at least approximately 99.9% pure and preferably at least approximately 99.99% pure.
- layer 14 contains silver
- this layer is of a material that contains at least approximately 2 wt.% silver (preferably at least approximately 5-10 wt.% silver); sheets 18a, 18b contain at least approximately 2 wt.% silver, preferably 5-15 wt.% or more. Suitable matenals contain approximately 0.05-0.50 g/cm 2 silver, with layer 14 preferably having a lower silver content than sheets 18.
- the metal content and specific resistance of layers 14, 18, as well as the thickness and uniformity of the metal coating, may vary broadly depending on the intended uses of device 10.
- Matenals containing less metal may be useful for some applications, as may those with higher specific resistances However, it should be understood that the matenals for layers 14, 18 are selected with a view to providing the needed amounts of free silver to the treatment site. Other metals with antibactenal and/or antifungal properties may also be useful for the practice of the present invention, including but not limited to gold, copper, aluminum, zinc, and combinations and alloys thereof.
- Layers 14, 18 are not only made of matenals having a sufficiently high content of silver (or other useful metal) to provide useful amounts of silver ions in vivo, but matenals that have an approximately uniform distnbution of silver.
- Non-uniform distnbutions may result in non-uniform treatment, since the amount of silver supplied to different areas of the target site may differ.
- the thickness of the silver coating on the fibers of layers 14, 18, like the basis weight of the fibers used to make the substrate, may vary broadly. Useful amounts of silver may be achieved with coatings no greater than 1 or 2 micrometers thick; however, the optimum coating thickness for any particular application depends on the basis weight and shape of the fibers, the type of fabnc (i.e., knit, loop, pile, etc.), the selected metal, and the intended application.
- the silver in layers 14, 18 is preferably in a form that, when device 10 is placed in contact with body tissues and moistened by a suitable liquid, releases silver ions by the passive dissolution of silver in ionic form from the metallic silver surface in a process known as ohgodynamic action. Thus, over a period of time, at least a portion of the available silver migrates to the immediately-adjacent tissues where it has useful antimicrobial and antifungal effects.
- metallized (i.e., metal- containmg, metal-coated, metal-plated) matenals wherein the metal atoms are firmly attached or bound to a fabnc substrate when dry, but are at least somewhat releasable in ionic form when wetted with a suitable liquid, are especially suitable for the practice of the present invention.
- layers 14, 18 may be made of matenals that contain silver (or other suitable metal) in the form of small crystals which tend to release free silver ions when wetted by saline, water, wound exudate, or other suitable liquid.
- Crystalline silver deposits of this type are believed to have a greater effective surface area than conventional silver-plated coatings, and therefore the capability of releasing more silver ions per umt coating weight, in shorter penods of time.
- other types of silver-containing matenals may also be useful.
- a multilayer device according to the present invention can be manufactured in a variety of useful shapes for use in different applications or different wound sites.
- Device 10 could, for example, include a slit or throughhole for accommodating a drain, catheter, external fixation device, or the like.
- a device 30 adapted for use on fingertip wounds has a thin, flexible outer layer 12, an inner layer with at least two adjacent silvered sheets 18 (for clanty, only the lowermost such sheet is shown), and an optional layer 14 between sheets 12 and 18 (Fig. 4).
- a layer of adhesive 20 coats the exposed inner side of layer 12.
- a plurality of radial slits 32 extend inwards from the periphery of dressing 30 to form a senes of flaps 34 about a central portion 36.
- Dressing 30 preferably has at least three or four slits 34 forming four flaps 34. However, a greater number of slits 32, such as the twelve slits 36 at approximately 30° intervals (Fig. 4), results in a better-fitting dressing. Portion 36 is centered on the fingertip with layer 18 adjacent to the skin and covenng the area to be treated. Flaps 34 are affixed to the skin proximal to the wound by adhesive 20. By overlapping flaps 34 approp ⁇ ately, the user can form dressing 30 into a "cap" that covers the fingertip.
- a dressing 30 approximately 2" (about 5 cm) in diameter with a central portion 36 approximately 1" (about 2 5 cm) in diameter is believed to be suitable for use on most fingertip wounds.
- dressing 30 can easily be made in different sizes to better fit small or large fingertips.
- Device 10 is inert until silver-containing layers 18a, 18b are wetted by any of a vanety of agents: water, wound exudate, or other suitable liquid. Then, at least some free silver ions are released from layers 18a, 18b and migrate from the fabnc substrate into the surrounding region. When placed so that at least one of silver-containing layers 18a, 18b contact the wound surface, naturally-occur ⁇ ng body fluids may be sufficient to activate this process. More frequently, device 10 is activated by moistening with a suitable liquid to promote the release of free ions. Distilled or stenle water is preferred, since tap water tends to vary in quality and frequently contains ions which interfere with the emission of silver from layers 18a, 18b. Hydrocolloid preparations such as DuoDermTM (manufactured by Convatec) may be useful in maintaining moisture in device 10, and do not interfere with silver ion emission from the device.
- DuoDermTM manufactured by Convatec
- two sheets 18a, 18b in device 10 is predicated upon the surprising discovery that a device with two or more silver-containing sheets is more effective than one with a single sheet, since two sheets have been found to provide at least the same amount of silver ions at the treatment site as a single sheet having twice the silver content.
- This property results in a device 10 that delivers more silver to the treated area, without the disadvantages of powdenng and flaking associated with fabncs having higher silver contents With a sufficiently large number of silver-containing sheets, however, the overall flexibility of the device and the added amount of free silver ions per each additional sheet tend to decrease.
- the optimum number of sheets 18a, 18b is best determined by a modest amount of expenmentation and observation for each particular application and combination of matenals.
- device 10 is self-ste ⁇ hzing, that is, layers 18a, 18b ste ⁇ ze themselves when wetted as a result of the antimicrobial effect of the silver contained in these layers. As a result, even though a device 10 is preferably used only once, it may be rinsed and reused whenever fresh devices are unavailable.
- silver ions are released from layers 18a, 18b into the adjacent tissues (if layer 14 contains silver, additional silver ions may also be released from layer 14).
- the rate of release generally rises to a maximum that depends on the silver content of the layers, then gradually decreases over a period of approximately 12-72 hours.
- an ion from the local wound environment i.e., chloride, etc.
- some of these other ions may bind spontaneously to the remaining silver on the fabnc.
- layers 14, 18a, 18b still contain silver at the end of the treatment penod, some of that silver will be unavailable for treatment purposes.
- device 10 may be rinsed and reused several times if desired, the device will eventually lose at least some of its antimicrobial activity.
- Mixed antibiotics were started after cultures of S. aureus, Pseudomonas and S. epider. were isolated; the S. aureus was noted to be resistant to all antibiotics. Dunng the first month following the injury, the infection was not controlled by antibiotic treatment, and began spreading into the soft tissues of the forefoot. Even though high forefoot amputations result in considerable compromise in ambulation and a high degree of disability, amputation of the forefoot well proximal to the infected area was recommended.
- Treatment with above-descnbed device 10 was initiated a month after the injury occurred.
- the dressing was changed twice daily; the foot was soaked for 15 minutes per day in a one-third dilution of commercial hydrogen peroxide.
- cultures of the wounds were negative, wound edema and redness had disappeared, and the patient began protected ambulation.
- the wounds healed well with normal, full- thickness skin with normal dermatoglyphic lines and full normal sensation. The patient thereafter resumed normal activity.
- a 56-year-old female was fitted with a lower denture after extraction of several teeth.
- a device 10 consisting of two layers of thin silver nylon matenal was applied over the mandibular ridge, positioned to cover the irritated and abraded areas. The denture was reinserted over device 10.
- the patient reported complete cessation of pain within 10 minutes. She wore the denture continuously for approximately 8 hours following application of the device 10. When the denture and device 10 were removed, the gum was pain-free and appeared normal.
- the patient was able to insert the denture on the following day without difficulty; she has expenenced no further pain, discomfort or swelling in the area.
- device 10 may include additional layers of matenals deemed to have useful properties, including but not limited to absorbent and adhesive materials.
- an absorbent layer 24 may be placed between sheets 18a, 18b (Fig. 3B), and/or an additional absorbent layer 26 between layers 14, 18a (Fig. 3C).
- Layers 14, 24, 26, if present, are soft, flexible, moisture-absorbing matenals as described above. Layers 14, 24, 26 need be no more than approximately 0.1-0.5 cm thick for most applications; however, thicker layers may be useful when device 10 is used in the care of relatively large draimng wounds.
- Device 40 is a multilayer wound packing material that includes at least one layer with an antimicrobial metal such as silver.
- Device 40 preferably includes at least two layers 42, 44 of thin, flexible, conformable, wettable, silver-containing fabnc such as that descnbed above for layers 18a, 18b of device 10.
- Layers 42, 44 need be no more than approximately 1-2 mm thick for most applications; however, thicker layers may be useful when packing material 10 is used in the care of draining wounds.
- layers 42, 44 are made of a flexible, conformable, absorbent matenal that contains at least approximately 2 wt.% silver, more preferably at least approximately 10-15 wt.% silver.
- the matenal is dimensionally stable and easily handled, whether wet or dry.
- Layers 42, 44 may be made by weaving, knitting, felting, blowing, or other convenient process, and consist of silver-coated or silver- impregnated fibers.
- Suitable matenals include felted ("pile") silver nylon, "matted” silver nylon, loop, and warp knit silver nylon fabncs made by Ommshield, Inc.; silver-impregnated fabncs made by Swift, Inc., Sauquoit Industnes and other manufacturers may also be useful for the practice of the invention.
- Device 40 may include additional layers of matenals deemed to be useful in wound packing applications, including not limited to one or more layers 46 of absorbent matenal (Fig. 5B).
- Layer (or layers) 46 like layers 42, 44, is flexible and conformable.
- Layer 46 if present, is a soft, flexible, moisture-absorbing matenal such as woven or nonwoven cotton, absorbent polyester, etc.
- Layer 46 need be no more than approximately 0.1-0.5 cm thick for most applications; however, thicker layers may be useful when device 40 is used in the care of draimng wounds.
- device 40 may include a layer of substantially moisture- impermeable matenal that, if present, helps direct fluids to layers 42, 44.
- the layers of device 40 are bonded together at their outer edges by any convenient technique, including but not limited to cnmping, embossing, application of heat and/or pressure via heated rollers, and biocompatible adhesives (Fig. 6A shows a 2-layer device 40 with cnmped edges 48a, 48b). Techniques such as heat/pressure bonding are preferred, since these avoid the use of additional matenals such as adhesives, fixatives, and so forth.
- layers 18a, 18b, layers 42, 44 consist of a dimensionally stable, biologically inert, easily handled and substantially non-adhering substrate to which silver (or some other metal with medically useful properties) has been added by any convenient technique known in the art.
- Individual fibers or microfibers can be coated and then worked (woven, knitted, crocheted, felted, blown, etc.) into a fabnc; alternatively, silver may be added to the fimshed fabric.
- Suitable substrate matenals include those listed above for layers 14, 18a, 18b, made by weaving, knitting, felting, blowing, or other process.
- Layers 42, 44 contain at least approximately 2 wt.% silver (or other metal with useful antimicrobial properties), more preferably, at least approximately 5-10 wt.% silver. Individual fibers can be coated and then worked into a fabnc; alternatively, silver may be added to the fimshed fabric.
- the wt.% silver, specific resistance and conductivity, the proportion of silver-containing fibers to plain (i.e., not containing silver) fibers, and other properties (fiber basis weight, shape, manufactunng technique) of useful fabrics may vary broadly. Matenals containing less metal may be useful for some applications, as may those with higher specific resistances.
- the matenals for layers 42, 44 are selected with a view to providing the needed amounts of free silver to the treatment site.
- the silver in layers 42, 44 releases silver ions by the passive dissolution from the metallic silver surface so that, over a period of time, at least a portion of the available silver migrates to the immediately-adjacent tissues where it has useful antimicrobial, antifungal and antiviral effects.
- silver ions are released from device 40 into the immediately-surrounding region. The rate of release generally rises to a maximum that depends on the silver content of material 10, then gradually decreases over a period of approximately 12-72 hours.
- each silver ion leaves the fabnc substrate of layers 42, 44, it is replaced by an ion from the local wound environment (i.e., chloride, etc.).
- the local wound environment i.e., chloride, etc.
- some of these other ions bind spontaneously to the silver crystals remaimng on the fabnc.
- layers 42, 44 may still contain silver at the end of several treatment periods, at least some of that silver will be unavailable for treatment purposes.
- devices 10, 40 are changed at least daily, and preferably at least twice daily. Devices 10, 40 may be washed and reused, particularly under field conditions, provision of fresh dressings is preferred.
- Device 40 may be used in the same manner as conventional wound packing materials. As illustrated by the following non-limiting example, a treatment device according to the present invention is especially useful in the care of antibiotic-resistant infections.
- a 71-year-old male construction worker (retired, insulin-dependent diabetic) developed an infection of the right foot at the 1st MAP joint which penetrated to the bone.
- the infection progressed into the entire foot and a below-knee amputation was required.
- the patient developed a similar infection on his left foot.
- the infection progressed into the first metatarsal.
- the patient was refened to an orthopedic surgeon for a below-knee amputation on the left foot. Due to his age and general physical condition, the patient would in all probability have been unable to ambulate with two lower leg prostheses.
- the cavity extended proximally along the first metatarsal with the most proximal area proximal to the surgical incision.
- the cavity was irregular in internal contour and required multiple strips of device 40 (in the form of 3 mm wide strips cut to approximately 5 cm lengths) for complete packing.
- the packed wound was covered with a dressing in the form of a 3" square (about 7.6 cm square) device 10. All packing and dressing components (i.e., devices 10, 40) were changed at 24-hour intervals.
- the cavity was irrigated with a 30% hydrogen peroxide solution between changes.
- EXAMPLE 4 A 72-year-old male underwent extraction of two lower teeth (#'s R2 and R3) under local anesthesia (mandibular nerve block). Immediately following extraction, a suitable quantity of device 40 (in the form of a 2 mm wide strip) was packed into the extraction site and covered with several gauze pads. Approximately 30 minutes following extraction, the mandibular nerve block began to wear off and sensation returned to the area. The post- anesthetic pain usually felt following a nerve block did not occur. The patient reported slight discomfort at the extraction site at that time, which was self-treated with an over-the-counter analgesic.
- the site and surrounding area were pain-free.
- the initial dressing was carefully removed to avoid disturbing the blood clot in the extraction sockets.
- a smaller amount of device 40 was then carefully inserted into the cavity and covered with device 10 (in the form of a 3 cm square pad), covered with a few 2.5 cm square gauze pads as a bite block. This combination dressing was kept in place for an additional 3 hours. The patient experienced no bleeding at the extraction site.
- Device 40 may be furnished in dimensions to suit a variety of applications, for example, 1-2" (about 2.5-5.0 cm) widths that can be cut to any needed length for covenng surgical incisions and relatively small wounds. Wider devices 40 can be provided for covenng large wounds such as burns and abrasions, and smaller, individually-packaged devices for small incisions, cuts, etc. Narrow strips (approximately 1-5 mm wide) may be useful for packing incisions, cavities, dental extraction sites, etc. If desired, device 40 can be covered by an appropnately-sized device 10 or other suitable dressing when in use The device can be packaged in a dispenser 50 (Fig. 6B), encased in paper or plastic to help maintain stenhty pnor to use, or delivered to the end user in any other convenient form
- a device 40 according to the present invention provides prophylactic and/or therapeutic activity to help prevent (or treat) infection, provide anti-inflammatory and anti- allogenic effects, promote healing and, in some cases, also provide local analgesia.
- device 40 When used as a wound packing material, device 40 is flexible and conformable to the area to be treated. The optimum dimensions and configurations of the device depend on the size and location of the area to be treated.
- a device according to the present invention can be used as a packing matenal, or applied immediately post-surgery after removal of all chemical skin disinfectants. Such a dressing is believed to provide a high degree of prophylaxis for post-operative infections.
- devices 10, 40 have significant bactencidal, anti-inflammatory, and anti-allogemc effects in the treated area, there are no systemic effects and no entry of silver ions into the circulatory system.
- device 40 is applied to the treatment site after appropnate preparation (debndement, irrigation, etc.). Depending on the area to be treated, device 40 may be moistened to promote the release of silver, which migrates into the treated area to minimize external and cross-contamination of the treatment site and help prevent bactenal and fungal infections, while not hindenng normal cell growth or repair. No toxic substance is introduced into the patient's body. Like above-described device 10, device 40 is preferably replaced at intervals of approximately 12-24 hours; however, the device may safely left in place for longer periods of time if circumstances so require (for example, under field conditions).
- device 40 is self-stenhzing, that is, the silver-containing fabnc of layers 42, 44 stenhzes itself in water. Therefore, while application of a fresh, unused device 40 every 12-24 hours is recommended, a patient can nnse and reuse the device, or leave it in place for several days, under emergency conditions.
- bactena including Brevibactenum epidermidis, Corynebactenum xerosis, Micrococcus lylae, and Staphylococcus epidermidis
- bactena including Brevibactenum epidermidis, Corynebactenum xerosis, Micrococcus lylae, and Staphylococcus epidermidis
- Resident populations of these bactena can be reduced by cleansing the skin.
- the odor returns as the remaimng bacteria quickly multiply in the relatively warm, relatively moist environment of the armpits, shod feet, etc.
- Fig. 7A there is shown an antimicrobial device 60 according to the present invention.
- device 60 consists of a single sheet of fabnc such as above-described sheet 18 (or sheets 42, 44) that contains sufficient silver or other bactencidal metal to provide beneficial antimicrobial effects.
- Sheet 18 is flexible, conformable, nonadhenng to intact skin and exposed tissues, and contains at least approximately 5 wt.% silver (however, fabrics with lower silver contents may also be useful). More preferably, sheet 18 contains at least approximately 10 wt.% or more silver.
- Device 60 may include at least two sheets 18a, 18b of such a fabric, as shown in Fig. 7B. If desired, one or both of sheets 18a, 18b may be at least somewhat moisture-absorbent. Sheets 18a, 18b need be no more than approximately 1-2 mm thick; however, thinner or thicker sheets may be also be useful. Sheets 18a, 18b are bonded together at edges 62a, 62b by any convenient technique, including but not limited to cnmping, embossing, application of heat and/or pressure via heated rollers. Biocompatible adhesives, while not preferred, may also be useful for the practice of the invention. Techmques such as heat/pressure bonding are preferred, since these avoid the use of additional matenals such as adhesives, fixatives, and so forth.
- Device 60 may include additional layers of matenals deemed to be useful, including not limited to a sheet 64 of absorbent matenal and/or a moisture-impermeable matenal that serves as an occlusive barner (Fig. 7C).
- Sheet 64 like sheets 18a, 18b, is flexible and conformable, preferably a soft, flexible, moisture-absorbing material such as woven or nonwoven cotton, absorbent polyester, etc. Sheet 64 need be no more than approximately 0.5-2.0 mm thick for most applications.
- the edges of sheet 64 may be attached to the edges of sheets 18a, 18b by any convenient technique, including but not limited to sewing, cnmping, embossing, application of heat and/or pressure via heated rollers, and biocompatible adhesives.
- sheet 64 may be a substantially moisture-impermeable matenal that acts as an occlusive barner to entrain moisture (including perspiration) and direct it towards the target.
- a device 60 is simply placed inside a sock, stump sock or liner, or shoe for use.
- Thermoplastic stump socks or liners are closely-fitting to provide good cushioning, reduction of chafing and skin irritation, and reduction of air pocket formation which leads to undesirable pistoning effects.
- these types of liners also provide a hospitable environment for the growth of odor-causing bacteria: users report pronounced "dirty sock" or locker-room type odors after even a few hours' use.
- a volunteer subject placed a 1" (about 2.5 cm) square device 60 into the bottom of a form-fitting thermoplastic stump sock worn as a liner with his conventional below-knee prosthesis.
- the liner and prosthesis were worn for a full day (approximately 14 hours).
- the subject reported no perceptible odor upon removal of the liner and prosthesis at the end of the day.
- Device 60 is small, thin, light in weight, flexible and conformable, so it does not interfere with the fit of the user's normal footgear (socks, shoes, etc.). Device 60 is inert until wetted by perspiration, other body fluid, or indeed any of a variety of fluids including water. Then, the bonds between the silver atoms and the fabric substrate are loosened and at least some free silver ions are released from the fabric of sheets 18a, 18b and act to inhibit the growth of microorganisms in the region, including at least some of the bacteria believed to cause objectionable locker-room type odors. The rate of release depends on factors that include the silver content of sheets 18a, 18b and the amount of moisture present.
- Device 60 may be furnished in any convenient dimensions, for example, 1-2" (about 2.5-5.0 cm) squares, or strips that can be cut to size for each individual user.
- the device can be packaged in a dispenser, encased in paper or plastic to help maintain its integrity prior to use, or be delivered to the end user in any other convenient form.
- An antimicrobial device 60 reduces odor by slowing the growth of odor-causing microorganisms, thereby enhancing the user's comfort and self-esteem.
- Device 60 is essentially imperceptible to the user when worn inside socks (including stump socks) or stockings, or inside shoes, boots, or sneakers.
- device 60 has no systemic effects, and its use does not result in entry of silver ions into the circulatory system. Use of device 60 does not lead to the development of either localized or systemic argyria.
- An antimicrobial treatment device can be made in a variety of configurations adapted to the intended use. Additional embodiments of the invention are shown in Figs. 8A and 8B.
- An iontophoretic treatment device 80 (Fig. 8A) has a first, electrically nonconductive outer layer 12, a second, intermediate layer 14, a inner layer with at least two sheets 18a, 18b, and, optionally, an edge adhesive 20 as described above for device 10.
- a snap- type connector 82 extends through layer 12 and makes electrical contact with layers 18a, 18b.
- Connector 82 is silver (or silver-plated). Applying current at the central connector 82 ensures an approximately umform current distnbution at the treatment site.
- Device 80 can be made in a variety of sizes, for example discs approximately 1-6" (about 2.5-15 cm) in diameter. For use as an anode in iontophoretic treatment, device 80 is large enough that adhesive 20 (if present) does not contact the wound.
- a return electrode 100 includes an outer layer 12, a layer 14, edge adhesive 20, and an electrical connector 102, generally as shown in Fig. 8B.
- Layer 14 is made of any suitable low-resistance material for making good elect ⁇ cal contact with intact skin.
- layer 14 may be a relatively thick (at least 3 mm) material with a silver content of at least approximately 10 wt.% (preferably at least approximately 15 wt.%).
- low- resistance, electncally-conductive thermoplastic matenals may also be useful.
- the inner sides of devices 90, 100 are protected with removable strips of material (not shown) that are peeled off just prior to use.
- Layer 14 of return electrode 100 is preferably made of a material that does not include chopped fibers. Many "matted"-type matenals are made of chopped fibers that are compressed into a mat. If these types of matenals are used m wound dressings, particularly on open wounds, there is a possibility that small fiber fragments will become separated from the main fabnc mass and be retained in the wound. Suitable matenals for layer 14 of devices 90, 100 (and layers 18a, 18b, 42, 44 of above-descnbed devices 10, 40, 50) include those made of small-diameter nylon microfibers that are spun into a single thread that is then silvered. Such matenals can have an electrical resistance as low as approximately 0.5 ⁇ /cm.
- low-resistance matenals are also suitable for use with the invention.
- silver-containing thermoplastic matenals such as those manufactured by the Chomencs Division of Parker Hannifin Corp. of Woburn, MA have resistances as low as 0.1 ⁇ /5 cm.
- the use of low-resistance matenals for layer 14 of devices 90, 100 results in decreased total circuit resistance at the point of skin contact, resulting in increased total circuit current and increased silver ion output. It is believed that use of lower-resistance matenals for layers 18a, 18b of device 10, layers 42, 44 of device 40, and layers 48a, 48b of device 50 may also result in increased silver ion output.
- devices 80, 100 are suitably positioned and secured to the patient's body, then connected to a power source to provide the desired iontophoretic treatment. Both devices can be made in any desired size and shape for a vanety of applications.
- a multilayer treatment device 120 has a thin, flexible outer layer 12, an intermediate layer 122, and at least one inner layer 18 of silver-containing fabnc as descnbed above (Fig. 9A).
- Layers 12 and 122 are preferably made of a thermoplastic material that softens when exposed to heat and returns to its onginal condition when cooled to room temperature. Suitable matenals include polyvinyl chlonde, nylon, fluorocarbon compounds, polyethylene, polyurethane, polystyrene, polypropylene, and various cellulosic and acrylic resins
- Layer 122 has a plurality of throughholes 124 ananged in any convenient pattern.
- a sponge 126 is inserted in each throughhole 124, so that sponges 126 contact silver-containing layer 18.
- Sponges 126 are made of a soft, flexible and conformable, moisture-absorbing material, including but not limited to cotton, polyester, rayon, dacron, polyurethane, polypropylene, acrylics and modacryhcs, polyvinyl acetate or other synthetic matenals, or combinations thereof, in woven, nonwoven, foam, or sponge-like form.
- Layer 122 and sponges 126 need be no more than a few millimeters thick for most applications. Sponges 126 are wetted to provide a moisture reservoir for silver-containing layer 18 when device 120 is in use.
- edges of layers 12, 18, and 122 may be attached together by any convenient technique, including but not limited to application of heat and pressure, embossing, cnmping, sonic welding, needle punching, and biocompatible adhesives such as above-described adhesive 16. However, techmques which avoid the use of adhesives, fixatives, and so forth are preferred.
- Another device 140 has layers 12, 18, and 122 (with sponge inserts 126) as described above for device 120 (Figs. 9B and 9C).
- a groove 142 is formed near a penmeter 144 of sheet 122, and a corresponding rib 146 near a penmeter 148 of sheet 12.
- Groove 142 and nb 146 form a fastener 150 that allows the user to wholly or partly remove outer layer 12 from device 140, for example, to add additional water or other liquid to sponges 126 so as to maintain an effective moisture reservoir for silver-containing layer 18.
- Layer 12 can easily be replaced simply by pushing rib 146 back into groove 142.
- An antimicrobial treatment device provides prophylactic and/or therapeutic activity to help prevent (or treat) infection, provide anti- lnflammatory and anti-allogenic effects, and promote healing.
- the device has sigmf leant bactencidal, anti-inflammatory, and anti-allogenic effects in the treated area, there are no systemic effects and no entry of silver ions into the circulatory system.
- the optimum content of silver (or other useful metal) depends on the particular application; thus, fabncs with silver contents outside the above-quoted ranges may also be useful for the practice of the invention.
- the device is flexible and conformable to the area to be treated.
- the optimum dimensions and configurations of the device depend on the size and location of the area to be treated, and include considerations of affixing the device in place, controlling moisture loss from the wound, and ensunng direct contact between the silver-containing material and the actual wound surface itself.
- a device 10 (or device 40) is applied to the patient's skin after appropnate surface preparation (the devices are preferably applied to dry skin so that adhesive 20 adheres well to the skin to hold the device in place).
- layer 14 may be moistened to promote the release of silver, which minimizes external and cross-contamination of the treatment site and helps prevent bactenal and fungal infections, while not hindenng normal cell growth or repair. No toxic substance is introduced into the patient's body.
- Devices 10, 40 are preferably replaced at intervals of approximately 12-24 hours; however, the devices may safely left in place for longer periods if circumstances so require (the devices may even be rinsed and reused if necessary, for example, under field conditions)
- a device according to the invention can be used for prophylactic treatment of fresh wounds and surgical incisions, treatment or prevention of early stage decubital ulcers ("bed sores"), therapeutic treatment of infected and traumatic wounds, and so forth.
- a treatment device with two or more silver-containing sheets is more effective than one with a single such sheet due to improved silver ion migration resulting in enhanced therapeutic effects. Even though only one of the two sheets typically contacts the treatment site, two sheets provide at least the same amount of silver ions at the site as a single sheet having twice the silver content. This property results in an device that delivers more silver, without the disadvantages of powdering and flaking associated with fabrics having higher silver contents.
- a fabnc with a sufficiently high concentration of silver releases silver ions at a steady rate for as long as the fabnc is in contact with the culture medium (in vitro or in vivo).
- Such fabncs are not known to cause allergic reactions, thus, their use prevents some of the potentially-harmful side effects associated with other silver delivery systems (silver sulfadiazine, silver thiosulfate).
- Devices that incorporate such fabncs are nonhazardous, conformable to the shape of the site to be treated, readily adaptable to diverse clinical situations, and safe and easy to use. When treating patients with extensive bums, a device according to the invention is less expensive, less cumbersome, and more effective than silver sulfadiazine cream.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU18119/00A AU1811900A (en) | 1998-11-03 | 1999-11-03 | Multilayer antibacterial treatment device |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10677898P | 1998-11-03 | 1998-11-03 | |
US10681898P | 1998-11-03 | 1998-11-03 | |
US10677998P | 1998-11-03 | 1998-11-03 | |
US60/106,778 | 1998-11-03 | ||
US60/106,818 | 1998-11-03 | ||
US60/106,779 | 1998-11-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000025726A2 true WO2000025726A2 (en) | 2000-05-11 |
WO2000025726A3 WO2000025726A3 (en) | 2000-09-28 |
Family
ID=27380190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/025893 WO2000025726A2 (en) | 1998-11-03 | 1999-10-03 | Multilayer antibacterial treatment device |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1811900A (en) |
WO (1) | WO2000025726A2 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002058748A1 (en) * | 2001-01-26 | 2002-08-01 | Camelot Technologies Limited | Absorbent pad for rendering hazardous liquids non-hazardous |
EP1269983A1 (en) * | 2001-06-22 | 2003-01-02 | Dragoco Gerberding & Co Aktiengesellschaft | Use of 1,2-Decanediol against germs which cause body malodour |
WO2003053484A1 (en) * | 2001-12-20 | 2003-07-03 | Noble Fiber Technologies | Wound dressings comprising metallic silver |
WO2003065877A2 (en) * | 2002-02-04 | 2003-08-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
US7240375B2 (en) | 2002-07-24 | 2007-07-10 | Christine Martz | Waistless underwear alternative secret pants shield |
EP1825754A2 (en) * | 2006-02-24 | 2007-08-29 | Pignatti Marzia | Disposable hygienic device for protecting the human skin against the spread of pathogenic micro-organisms |
US7270721B2 (en) * | 2003-06-23 | 2007-09-18 | Beiersdorf Ag | Antimicrobial wounddressing |
US7329792B2 (en) | 2003-02-04 | 2008-02-12 | Damage Control Surgical Technologies, Inc. | Method and apparatus for hemostasis |
US7805768B2 (en) | 2002-06-24 | 2010-10-05 | Christine Martz | Liquid penetration shields for outer garments |
AU2005337465B2 (en) * | 2005-10-21 | 2011-04-07 | Argentum International, Llc | Medical device |
US7943810B2 (en) | 2003-02-04 | 2011-05-17 | Buckman Robert F | Method and apparatus for hemostasis |
US7941872B2 (en) | 2002-06-24 | 2011-05-17 | Christine Martz | Waistless underwear alternative secret pants shield |
US8042194B2 (en) | 2002-10-08 | 2011-10-25 | Trudy Connor | Garment liner |
AU2010100968B4 (en) * | 2010-09-03 | 2011-12-08 | Austming Trade Pty Ltd | A mat |
US8357831B2 (en) | 2003-02-04 | 2013-01-22 | Buckman Robert F | Surgical packing devices |
US8383527B2 (en) | 2003-06-23 | 2013-02-26 | Beiersdorf Ag | Antimicrobial composite |
US20190111240A1 (en) * | 2016-11-28 | 2019-04-18 | The Jenex Corporation | Devices for applying a topical treatment |
DE102019122253A1 (en) * | 2019-08-19 | 2021-02-25 | Hanse-Lopack Riskau GmbH | Hygienic plaster to absorb sweat |
WO2021225819A3 (en) * | 2020-04-27 | 2022-02-10 | Ion Defense Technologies | Article of personal protective equipment |
US20230277382A1 (en) * | 2015-09-24 | 2023-09-07 | Medline Industries, Lp | Wound dressing materials and methods of making thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5782787A (en) * | 1993-02-15 | 1998-07-21 | Smith & Nephew Plc | Moisture-responsive absorbent wound dressing |
-
1999
- 1999-10-03 WO PCT/US1999/025893 patent/WO2000025726A2/en active Application Filing
- 1999-11-03 AU AU18119/00A patent/AU1811900A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5782787A (en) * | 1993-02-15 | 1998-07-21 | Smith & Nephew Plc | Moisture-responsive absorbent wound dressing |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002058748A1 (en) * | 2001-01-26 | 2002-08-01 | Camelot Technologies Limited | Absorbent pad for rendering hazardous liquids non-hazardous |
EP1269983A1 (en) * | 2001-06-22 | 2003-01-02 | Dragoco Gerberding & Co Aktiengesellschaft | Use of 1,2-Decanediol against germs which cause body malodour |
WO2003000220A2 (en) * | 2001-06-22 | 2003-01-03 | Dragoco Gerberding & Co. Ag | Use of 1,2-decandiol for combating germs causing body odour |
WO2003000220A3 (en) * | 2001-06-22 | 2003-03-27 | Dragoco Gerberding Co Ag | Use of 1,2-decandiol for combating germs causing body odour |
WO2003053484A1 (en) * | 2001-12-20 | 2003-07-03 | Noble Fiber Technologies | Wound dressings comprising metallic silver |
US7385101B2 (en) | 2001-12-20 | 2008-06-10 | Noble Fiber Technologies, Llc | Antibiotic textile materials suitable for wound dressings and wound dressings incorporating the same |
WO2003065877A3 (en) * | 2002-02-04 | 2004-02-26 | Damage Control Surgical Techno | Method and apparatus for improved hemostasis and damage control operations |
US6998510B2 (en) | 2002-02-04 | 2006-02-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
WO2003065877A2 (en) * | 2002-02-04 | 2003-08-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
US7941872B2 (en) | 2002-06-24 | 2011-05-17 | Christine Martz | Waistless underwear alternative secret pants shield |
US7805768B2 (en) | 2002-06-24 | 2010-10-05 | Christine Martz | Liquid penetration shields for outer garments |
US7240375B2 (en) | 2002-07-24 | 2007-07-10 | Christine Martz | Waistless underwear alternative secret pants shield |
US8042194B2 (en) | 2002-10-08 | 2011-10-25 | Trudy Connor | Garment liner |
US7943810B2 (en) | 2003-02-04 | 2011-05-17 | Buckman Robert F | Method and apparatus for hemostasis |
US8252970B2 (en) | 2003-02-04 | 2012-08-28 | Damage Control Surgical Technologies, Inc. | Method and apparatus for hemostasis |
US8759602B2 (en) | 2003-02-04 | 2014-06-24 | Robert F. Buckman | Method and apparatus for hemostasis |
US7329792B2 (en) | 2003-02-04 | 2008-02-12 | Damage Control Surgical Technologies, Inc. | Method and apparatus for hemostasis |
US8357831B2 (en) | 2003-02-04 | 2013-01-22 | Buckman Robert F | Surgical packing devices |
US9101682B2 (en) | 2003-06-23 | 2015-08-11 | Beiersdorf Ag | Antimicrobial composite |
US7270721B2 (en) * | 2003-06-23 | 2007-09-18 | Beiersdorf Ag | Antimicrobial wounddressing |
US8383527B2 (en) | 2003-06-23 | 2013-02-26 | Beiersdorf Ag | Antimicrobial composite |
AU2005337465B2 (en) * | 2005-10-21 | 2011-04-07 | Argentum International, Llc | Medical device |
AU2005337465A8 (en) * | 2005-10-21 | 2011-08-04 | Argentum International, Llc | Medical device |
AU2005337465B8 (en) * | 2005-10-21 | 2011-08-04 | Argentum International, Llc | Medical device |
EP1825754A2 (en) * | 2006-02-24 | 2007-08-29 | Pignatti Marzia | Disposable hygienic device for protecting the human skin against the spread of pathogenic micro-organisms |
EP1825754A3 (en) * | 2006-02-24 | 2009-05-06 | Pignatti Marzia | Disposable hygienic device for protecting the human skin against the spread of pathogenic micro-organisms |
AU2010100968B4 (en) * | 2010-09-03 | 2011-12-08 | Austming Trade Pty Ltd | A mat |
US20230277382A1 (en) * | 2015-09-24 | 2023-09-07 | Medline Industries, Lp | Wound dressing materials and methods of making thereof |
US20190111240A1 (en) * | 2016-11-28 | 2019-04-18 | The Jenex Corporation | Devices for applying a topical treatment |
US11344707B2 (en) * | 2016-11-28 | 2022-05-31 | Therma Bright Inc. | Devices for applying a topical treatment |
DE102019122253A1 (en) * | 2019-08-19 | 2021-02-25 | Hanse-Lopack Riskau GmbH | Hygienic plaster to absorb sweat |
WO2021225819A3 (en) * | 2020-04-27 | 2022-02-10 | Ion Defense Technologies | Article of personal protective equipment |
Also Published As
Publication number | Publication date |
---|---|
AU1811900A (en) | 2000-05-22 |
WO2000025726A3 (en) | 2000-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8293964B2 (en) | Multilayer laminate wound dressing | |
WO2000025726A2 (en) | Multilayer antibacterial treatment device | |
JP4424847B2 (en) | Multilayer conductive device with wound healing and analgesic properties | |
US7291762B2 (en) | Multilayer conductive appliance having wound healing and analgesic properties | |
US8449514B2 (en) | Conductive wound dressings and methods of use | |
US8801681B2 (en) | Medical device | |
US8093444B2 (en) | Multilayer conductive appliance having wound healing and analgesic properties | |
ES2430688T3 (en) | Medical device | |
AU2008229658B2 (en) | Conductive wound dressings and methods of use | |
WO2001060599A1 (en) | Antimicrobial composition and articles | |
AU768317B2 (en) | Multilayer conductive appliance having wound healing and analgesic properties | |
CA2597035A1 (en) | Multilayer conductive appliance having wound healing and analgesic properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase in: |
Ref country code: AU Ref document number: 2000 18119 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |